ASND
Price:
$230.83
Market Cap:
$12.49B
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding ...[Read more]
Industry
Biotechnology
IPO Date
2015-01-28
Stock Exchange
NASDAQ
Ticker
ASND
According to Ascendis Pharma A/S’s latest financial reports and current stock price. The company's current PE Ratio is 26.29. This represents a change of -158.81% compared to the average of -44.70 of the last 4 quarters.
The mean historical PE Ratio of Ascendis Pharma A/S over the last ten years is -18.83. The current 26.29 PE Ratio has changed -14060.80% with respect to the historical average. Over the past ten years (40 quarters), ASND's PE Ratio was at its highest in in the March 2026 quarter at 4.77. The PE Ratio was at its lowest in in the December 2025 quarter at -84.02.
Average
-18.83
Median
-16.69
Minimum
-50.13
Maximum
-7.45
Discovering the peaks and valleys of Ascendis Pharma A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 146.25%
Maximum Annual PE Ratio = -7.45
Minimum Annual Increase = -38.62%
Minimum Annual PE Ratio = -50.13
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -50.13 | 146.25% |
| 2024 | -20.36 | 52.77% |
| 2023 | -13.33 | 21.52% |
| 2022 | -10.97 | -35.11% |
| 2021 | -16.90 | 2.55% |
| 2020 | -16.48 | -37.69% |
| 2019 | -26.45 | 53.48% |
| 2018 | -17.23 | 91.29% |
| 2017 | -9.01 | 20.93% |
| 2016 | -7.45 | -38.62% |
The current PE Ratio of Ascendis Pharma A/S (ASND) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-27.94
5-year avg
-22.34
10-year avg
-18.83
Ascendis Pharma A/S’s PE Ratio is greater than Ionis Pharmaceuticals, Inc. (-37.25), greater than BridgeBio Pharma, Inc. (-17.67), greater than Revolution Medicines, Inc. (-22.92), greater than Roivant Sciences Ltd. (-69.84), greater than Summit Therapeutics Inc. (-9.82), greater than Guardant Health, Inc. (-38.87), greater than Madrigal Pharmaceuticals, Inc. (-39.51), greater than Exelixis, Inc. (16.64), less than BioMarin Pharmaceutical Inc. (39.06), greater than Moderna, Inc. (-7.85),
| Company | PE Ratio | Market cap |
|---|---|---|
| -37.25 | $12.25B | |
| -17.67 | $12.98B | |
| -22.92 | $34.65B | |
| -69.84 | $22.61B | |
| -9.82 | $10.67B | |
| -38.87 | $17.47B | |
| -39.51 | $11.66B | |
| 16.64 | $13.05B | |
| 39.06 | $10.57B | |
| -7.85 | $25.38B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ascendis Pharma A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ascendis Pharma A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ascendis Pharma A/S's PE Ratio?
How is the PE Ratio calculated for Ascendis Pharma A/S (ASND)?
What is the highest PE Ratio for Ascendis Pharma A/S (ASND)?
What is the 3-year average PE Ratio for Ascendis Pharma A/S (ASND)?
What is the 5-year average PE Ratio for Ascendis Pharma A/S (ASND)?
How does the current PE Ratio for Ascendis Pharma A/S (ASND) compare to its historical average?